Erasca News

Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating

TipRanksApr 3 01:47 ET

Erasca Analyst Ratings

BenzingaApr 2 12:15 ET

Erasca's Strong Clinical Data and Enhanced Financial Position Support Buy Rating

TipRanksMar 28 18:35 ET

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)

TipRanksMar 28 06:21 ET

Erasca Analyst Ratings

BenzingaMar 28 06:12 ET

Erasca Analyst Ratings

BenzingaMar 11 09:58 ET

Capital One Initiates Coverage On Erasca With Overweight Rating, Announces Price Target of $8

BenzingaMar 11 10:00 ET

Erasca's Strategic Oncology Focus and Pipeline Potential: An Overweight Rating With a Bright Outlook

TipRanksMar 11 07:15 ET

B of A Securities Downgrades Erasca to Neutral, Lowers Price Target to $6

BenzingaJan 5 09:13 ET

Erasca Analyst Ratings

BenzingaJan 5 09:12 ET

Strong Buy Rating for Erasca's Stock on FDA Fast Track Designation and Market Expansion Potential

TipRanksDec 13, 2023 04:15 ET

Erasca Analyst Ratings

BenzingaNov 29, 2023 12:13 ET

Erasca Analyst Ratings

BenzingaNov 28, 2023 11:12 ET

Erasca's Strategic Focus on MAPK Pathway in SEACRAFT-2 Study Warrants a Buy Rating

TipRanksNov 28, 2023 10:55 ET

HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating

MT NewswiresNov 28, 2023 10:52 ET

Erasca's Promising Future: Data Timelines, Financial Stability, and Fast-to-Market Opportunities Support Buy Rating

TipRanksNov 10, 2023 11:30 ET

Analysts Are Bullish on Top Technology Stocks: Erasca (ERAS), Synaptics (SYNA)

TipRanksNov 10, 2023 07:02 ET

Promising Future Growth and Clinical Milestones: A Buy Rating for Erasca

TipRanksNov 9, 2023 18:55 ET

HC Wainwright & Co. Initiates Coverage On Erasca With Buy Rating, Announces Price Target of $10

BenzingaOct 11, 2023 07:22 ET

Erasca Analyst Ratings

BenzingaOct 11, 2023 07:20 ET